Skip to content
Back to products

GastroPanel® Quick Test

GastroPanel® Quick Test helps clinicians triage patients with stomach symptoms before gastroscopy, identifying who needs further investigation and who doesn’t. A finger-prick blood test with results in 15 minutes, designed for use at the point of care.

Why choose GastroPanel® Quick Test

Triage patients before gastroscopy

Results in 15 minutes using the GastroPanel reader

Negative predictive value of 91%

No laboratory required

BIOHIT GastroPanel Quick Test NT

Interested in this product? Get in touch

Our team of experts are on hand to answer any questions you may have about this product, or any of our other offerings.

  • Product code: Product code: 602410 (30 tests for plasma and venous whole blood)
  • Product code: Product code: 602420 (30 tests for finger prick whole blood)

Avoid invasive testing

Not every patient with stomach symptoms needs a gastroscopy. Yet endoscopy units across the NHS are under increasing pressure to manage growing demand, with thousands of patients referred for gastroscopy each year without prior triage. GastroPanel® Quick Test is a finger-prick blood test that assesses four gastric biomarkers – pepsinogen I, pepsinogen II, gastrin-17 and H. pylori antibodies – that identifies which patients need further investigation and which don’t. With results available in 15 minutes at the point of care, clinicians can make confident triage decisions before any decision to scope is made, reducing unnecessary procedures and ensuring patients who genuinely need gastroscopy are seen sooner.

Better gastroscopy outcomes

For patients who test positive, GastroPanel Quick Test improves the quality of the gastroscopy itself. In England, approximately 8.5% of upper gastrointestinal cancers are diagnosed after a previous endoscopy failed to detect the disease. GastroPanel helps address this by equipping clinicians with detailed information about the condition of the gastric mucosa before the procedure, enabling a more targeted examination, more appropriate biopsy decisions and reducing the risk of missed diagnoses.

Transform your gastroscopy pathway

The benefits extend beyond the individual patient. Gastroscopy is a resource-intensive procedure requiring a team of clinical and administrative staff. By reducing unnecessary gastroscopies, GastroPanel Quick Test frees up endoscopy capacity, reduces cost and clinical time across the pathway, and ensures that stretched endoscopy services can focus on the patients who need them most. As a point-of-care test requiring no laboratory infrastructure, GastroPanel Quick Test is suitable for departments of any size making pathway change practical as well as clinically compelling.

What is atrophic gastritis?

Atrophic gastritis is a chronic condition in which the lining of the stomach becomes inflamed and the gastric glands are gradually lost. It is most commonly caused by Helicobacter pylori infection or autoimmune disease. Left undetected, atrophic gastritis can lead to serious complications including vitamin B12, calcium and iron malabsorption, and carries an increased risk of gastric adenocarcinoma. Early identification is key to preventing disease progression.

What causes dyspepsia?

Dyspepsia, commonly known as indigestion, refers to persistent pain or discomfort in the upper abdomen. Causes range from lifestyle factors such as diet and stress to underlying conditions including Helicobacter pylori infection, atrophic gastritis, peptic ulcer disease and, in some cases, gastric cancer. Identifying the underlying cause early is important for effective management and to avoid unnecessary investigations.

How does GastroPanel Quick Test work?

GastroPanel Quick Test measures four gastric biomarkers – pepsinogen I, pepsinogen II, gastrin-17 and H. pylori antibodies – from a finger-prick blood sample. These biomarkers provide clinicians with information about the condition of the gastric mucosa, helping to identify patients at risk of atrophic gastritis and H. pylori infection. Results are delivered in 15 minutes and automatically interpreted by the GP Reader.

How accurate is GastroPanel Quick Test?

GastroPanel Quick Test has a negative predictive value of 91%, meaning clinicians can confidently rule out serious gastric conditions in the majority of patients. Its diagnostic accuracy was confirmed in a UK clinical study conducted at Homerton University Hospital NHS Foundation Trust, published in BMJ Open Gastroenterology in 2025, which demonstrated that GastroPanel can identify patients at high risk of gastric cancer with over 90% accuracy. Unpublished findings from the CyGIM study at Addenbrooke’s Hospital further demonstrate a strong correlation between GastroPanel’s pepsinogen I/II ratio and OLGA staging, showing excellent discrimination between clinically relevant and non-significant gastric atrophy.

How does GastroPanel Quick Test fit into the gastroscopy pathway?

GastroPanel Quick Test is designed to be used before any decision to refer a patient for gastroscopy is made. By assessing the condition of the gastric mucosa at the point of care, it helps clinicians identify which patients need further investigation and which can be safely managed without gastroscopy. For patients who test positive, GastroPanel results also help clinicians approach the gastroscopy with greater focus and precision.

Can GastroPanel Quick Test be used without a laboratory?

Yes, GastroPanel Quick Test is a point-of-care test that requires no laboratory infrastructure. Results are delivered in 15 minutes and automatically interpreted by the GP Reader, making it suitable for use in any clinical setting regardless of department size or patient volume. This removes the practical barrier of batch testing associated with laboratory-based ELISA methods.

What biomarkers does GastroPanel Quick Test measure?

GastroPanel Quick Test measures four gastric biomarkers: pepsinogen I, pepsinogen II, gastrin-17 and H. pylori IgG antibodies. Together these biomarkers provide a comprehensive assessment of the gastric mucosa, enabling clinicians to identify atrophic gastritis, H. pylori infection and abnormal gastric acid output from a single finger-prick blood sample.

How quickly are results available?

Results are available in 15 minutes. The GP Reader automatically interprets the results, removing the need for manual interpretation and reducing the risk of error. This makes GastroPanel Quick Test suitable for use at the point of care, enabling rapid clinical decision making without the delays associated with laboratory testing.

How does GastroPanel Quick Test help reduce unnecessary gastroscopies?

Not every patient with stomach symptoms needs a gastroscopy. The PROSPERO study estimated that only 15% of patients referred for upper GI endoscopy had clinically significant pathological findings, suggesting that around 85% of patients could potentially avoid or safely delay an invasive investigation through better risk stratification. GastroPanel Quick Test gives clinicians an objective, evidence-based way to assess gastric mucosal health before any decision to scope is made, identifying patients who don’t need further investigation, freeing up endoscopy capacity and ensuring that patients with serious conditions are seen sooner.

What clinical evidence supports GastroPanel Quick Test?

GastroPanel Quick Test is supported by a growing body of clinical evidence. A landmark UK study conducted at Homerton University Hospital NHS Foundation Trust, published in BMJ Open Gastroenterology in 2025, confirmed its diagnostic accuracy in identifying patients at high risk of gastric cancer with over 90% accuracy. Unpublished findings from the CyGIM study at Addenbrooke’s Hospital demonstrate a strong correlation between GastroPanel’s pepsinogen I/II ratio and OLGA staging, showing excellent discrimination between clinically relevant and non-significant gastric atrophy. British Society of Gastroenterology guidelines state that serum pepsinogen I and the pepsinogen I/II ratio – alone or in combination with H. pylori serology and gastrin-17 – can identify individuals with extensive atrophic gastritis.

  • Test format: Lateral flow immunoassay with automatic GP Reader

  • Sample type: Finger-prick whole blood or venous whole blood

  • Biomarkers measured: Pepsinogen I, Pepsinogen II, Gastrin-17, H. pylori IgG antibodies

  • Test time: 15 minutes

  • Storage temperature: 2–8°C

  • Negative predictive value: 91%

  • Pack size: 30 tests per kit